Effi cacy of GNP combined chemotherapy in treatment for refractory and relapse non-hodgkin lymphoma

Objective Toobserve the efficacy of GNP (gemcitabine, nedaplatin, methyl prednisolone) combinedchemotherapy in treatment for refractory and relapse non-hodgkin lymphoma (NHL). Methods The efficacy and adverse responses of 30 patients with refractory and relapse NHL whohadvoluntarily receivedGNP chemotherapy in our hospital from January 2009 toJuly 2013 were retrospectively analyzed. Of the 30 cases, 12 cases were refractory, 13 cases were relapse and 5 cases were progression. 18 cases were B cell lymphoma and 12 cases were T or NK/T cell lymphoma. The median circles of therapy-receiving were 2 circles (2-7 circles). Results The efficacy of GNP combinedchemotherapy in treatment for refractory and relapse NHL showedcomplete remission (CR) in 3 cases, partial remission (PR) in 20 cases, stable disease (SD) in 7 cases. The over response rate (ORR) was 76.7%, and the over survival rate for 1 year reached86.7%. The progression free survival (PFS) reached40% with the median PFS of 10 months (95% CI for 5.8-14.2 months). The adverse responses were slight and the endurement was fine. Conclusion There is favorable efficacy for GNP combinedchemotherapy in treatment for refractory and relapse non-hodgkin lymphoma.